Overview
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others.
For Investor Relations inquiries, please contact PureTech's Investor Relations team at: ir@puretechhealth.com.
View our corporate deck.
Share Price
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Half Year Report 2021
Corporate Presentation
Cash at Parent Level
$409.7M PureTech Level Cash and Cash Equivalents as of June 30, 20211
1This represents a non-IFRS number. For a reconciliation of this number to IFRS, please see below:
Consolidated Cash Reserves is a non IFRS-measure which consists of cash, cash equivalents and short-term investments held at PureTech Health plc and consolidated subsidiaries. PureTech Level Cash Reserves is a non-IFRS measure which consists of cash, cash equivalents and short-term investments held at PureTech Health plc and only wholly-owned subsidiaries. PureTech Level Cash and Cash Equivalents is a non-IFRS measure which consists of cash and cash equivalents held at PureTech Health plc and only wholly-owned subsidiaries.